miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin Pathway
Nasopharyngeal carcinoma (NPC) is prevalent in East and Southeast Asia. In a previous study, Epstein-Barr virus (EBV)-miR-BART22 induces tumor metastasis and stemness and is significantly involved in NPC progression. In the present study, we observed that miR-4721 is induced by EBV-miR-BART22 throug...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253120302924 |
id |
doaj-ae384af854914639b42a9e02f0094056 |
---|---|
record_format |
Article |
spelling |
doaj-ae384af854914639b42a9e02f00940562020-12-05T04:20:39ZengElsevierMolecular Therapy: Nucleic Acids2162-25312020-12-0122557571miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin PathwayZiBo Tang0WeiFeng Chen1Yan Xu2Xian Lin3Xiong Liu4YongHao Li5YiYi Liu6ZhiJian Luo7Zhen Liu8WeiYi Fang9MengYang Zhao10Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, ChinaCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, ChinaCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, ChinaCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, ChinaDepartment of Otolaryngology, Head and Neck Surgery, Nanfang Hospital, Southern Medical University, 510515 Guangzhou, ChinaCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, ChinaCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, ChinaCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, ChinaKey Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, 511436 Guangzhou, China; Corresponding author: Zhen Liu, PhD, Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, 511436 Guangzhou, China.Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, China; Corresponding author: WeiYi Fang, PhD, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, China.Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315 Guangzhou, China; Department of Oncology, The People’s Hospital of Zhengzhou University, 450003 Zhengzhou, China; Corresponding author: MengYang Zhao, PhD, Department of Oncology, The People’s Hospital of Zhengzhou University, 450003 Zhengzhou, China.Nasopharyngeal carcinoma (NPC) is prevalent in East and Southeast Asia. In a previous study, Epstein-Barr virus (EBV)-miR-BART22 induces tumor metastasis and stemness and is significantly involved in NPC progression. In the present study, we observed that miR-4721 is induced by EBV-miR-BART22 through phosphatidylinositol 3-kinase (PI3K)/AKT/c-JUN/Sp1 signaling to promote its transcription. In a subsequent study, we observed that miR-4721 serves as a potential oncogenic factor promoting NPC cell cycle progression and cell proliferation in vitro and in vivo. Mechanism analysis indicated that miR-4721 directly targetes GSK3β and reduces its expression, which therefore elevates β-catenin intra-nuclear aggregation and activates its downstream cell cycle factors, including CCND1 and c-MYC. In clinical samples, miR-4721 and GSK3β are respectively observed to be upregulated and downregulated in NPC progression. Elevated expression of miR-4721 is positively associated with clinical progression and poor prognosis. Our study first demonstrated that miR-4721 as an oncogene is induced by EBV-miR-BART22 via modulating PI3K/AKT/c-JUN/Sp1 signaling to target GSK3β, which thus activates the WNT/β-catenin-stimulated cell cycle signal and enhances the tumorigenic capacity in NPC. miR-4721 may be a potential biomarker or therapeutic target in NPC treatment in the future.http://www.sciencedirect.com/science/article/pii/S2162253120302924epithelial cell carcinomaEBVonco-miRcell cycleproliferationtumor marker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
ZiBo Tang WeiFeng Chen Yan Xu Xian Lin Xiong Liu YongHao Li YiYi Liu ZhiJian Luo Zhen Liu WeiYi Fang MengYang Zhao |
spellingShingle |
ZiBo Tang WeiFeng Chen Yan Xu Xian Lin Xiong Liu YongHao Li YiYi Liu ZhiJian Luo Zhen Liu WeiYi Fang MengYang Zhao miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin Pathway Molecular Therapy: Nucleic Acids epithelial cell carcinoma EBV onco-miR cell cycle proliferation tumor marker |
author_facet |
ZiBo Tang WeiFeng Chen Yan Xu Xian Lin Xiong Liu YongHao Li YiYi Liu ZhiJian Luo Zhen Liu WeiYi Fang MengYang Zhao |
author_sort |
ZiBo Tang |
title |
miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin Pathway |
title_short |
miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin Pathway |
title_full |
miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin Pathway |
title_fullStr |
miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin Pathway |
title_full_unstemmed |
miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin Pathway |
title_sort |
mir-4721, induced by ebv-mir-bart22, targets gsk3β to enhance the tumorigenic capacity of npc through the wnt/β-catenin pathway |
publisher |
Elsevier |
series |
Molecular Therapy: Nucleic Acids |
issn |
2162-2531 |
publishDate |
2020-12-01 |
description |
Nasopharyngeal carcinoma (NPC) is prevalent in East and Southeast Asia. In a previous study, Epstein-Barr virus (EBV)-miR-BART22 induces tumor metastasis and stemness and is significantly involved in NPC progression. In the present study, we observed that miR-4721 is induced by EBV-miR-BART22 through phosphatidylinositol 3-kinase (PI3K)/AKT/c-JUN/Sp1 signaling to promote its transcription. In a subsequent study, we observed that miR-4721 serves as a potential oncogenic factor promoting NPC cell cycle progression and cell proliferation in vitro and in vivo. Mechanism analysis indicated that miR-4721 directly targetes GSK3β and reduces its expression, which therefore elevates β-catenin intra-nuclear aggregation and activates its downstream cell cycle factors, including CCND1 and c-MYC. In clinical samples, miR-4721 and GSK3β are respectively observed to be upregulated and downregulated in NPC progression. Elevated expression of miR-4721 is positively associated with clinical progression and poor prognosis. Our study first demonstrated that miR-4721 as an oncogene is induced by EBV-miR-BART22 via modulating PI3K/AKT/c-JUN/Sp1 signaling to target GSK3β, which thus activates the WNT/β-catenin-stimulated cell cycle signal and enhances the tumorigenic capacity in NPC. miR-4721 may be a potential biomarker or therapeutic target in NPC treatment in the future. |
topic |
epithelial cell carcinoma EBV onco-miR cell cycle proliferation tumor marker |
url |
http://www.sciencedirect.com/science/article/pii/S2162253120302924 |
work_keys_str_mv |
AT zibotang mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT weifengchen mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT yanxu mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT xianlin mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT xiongliu mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT yonghaoli mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT yiyiliu mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT zhijianluo mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT zhenliu mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT weiyifang mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway AT mengyangzhao mir4721inducedbyebvmirbart22targetsgsk3btoenhancethetumorigeniccapacityofnpcthroughthewntbcateninpathway |
_version_ |
1724399960912297984 |